Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.57B, -1.7% YoY · Filed Oct 30, 2026
Organon & Co. (OGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.6 billion and net income of $164.0 million. Free cash flow was $326.0 million. As of Sep 30, 2026 it held $1.5 billion in cash and investments and $8.6 billion in total debt.
Revenue
$1.57B
-1.7% vs year-ago quarter
Net income
$164.00M
+2.5% vs year-ago quarter
Operating cash flow
$370.00M
+40.2% vs year-ago quarter
Free cash flow
$326.00M
+49.5% vs year-ago quarter
EPS
$0.60
-1.6% vs year-ago quarter
Dividend per share
$0.02
+0.0% vs year-ago quarter
Shares outstanding
262.62M
+1.0% vs year-ago quarter
Net cash
$-7.10B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OGN (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Jersey City, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821825
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.5B | $1.5B | $1.6B |
| Net income | $164.0M | $108.0M | $146.0M | -$205.0M | $160.0M |
| Diluted EPS | $0.60 | $0.40 | $0.55 | -$0.78 | $0.61 |
| Operating cash flow | $370.0M | $107.0M | $225.0M | $141.0M | $264.0M |
| Free cash flow | $326.0M | $65.0M | $188.0M | $96.0M | $218.0M |
| Total assets | $13.4B | $13.2B | $13.0B | $12.9B | $13.6B |
| Total liabilities | $12.2B | $12.2B | $12.1B | $12.1B | $12.6B |
| Stockholders' equity | $1.2B | $1.0B | $903.0M | $752.0M | $906.0M |
| Cash and investments | $1.5B | $1.1B | $1.1B | $574.0M | $672.0M |
| Total debt | $8.6B | $8.6B | $8.6B | $8.8B | $8.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 30, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 31, 2026 | Jul 31, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 17, 2026 |
All 461 Organon & Co. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.